Shanghai RAAS Blood Products Co., Ltd.

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
7.07 ^CNY	+0.43%		+3.51%	-11.62%

Apr. 15	Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees	MT
Apr. 10	Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake	RE

Shanghai RAAS Blood Products Co., Ltd. Announces 2020 Final Dividend, Payable on 02 July 2021

June 25, 2021 at 03:42 pm EDT

Shanghai RAAS Blood Products Co., Ltd. announces 2020 final dividend of tax included CNY 0.25000000 per 10 shares for A shares, payable on 02 July 2021. Record date is 01 July 2021 and Ex-date is 02 July 2021.

Latest news about Shanghai RAAS Blood Products Co., Ltd.

Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees	Apr. 15	MT
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake	Apr. 10	RE
Grifols Expects H1 Completion of Shanghai RAAS Stake Sale to Haier	Apr. 10	MT
Grifols: under Moody's watch, the share price plunges	Mar. 06	CF
RAAS Blood Products Gets Regulatory Nod to Trial Drug for Bleeding Disorders	Mar. 05	MT
Grifols says due diligence was carried out on Shanghai RAAS stake sale	Mar. 01	RE
Grifols says due diligence done, Shanghai RAAS stake sale to go ahead	Mar. 01	RE
Grifols' shares tumble as restructuring costs hit annual profit	Feb. 29	RE
S&P Maintains Grifols' Rating, Stable Outlook Amid Expected Deleveraging	Jan. 22	MT
S&P keeps Grifols at 'B+', sees leverage decreasing in 2024	Jan. 19	RE
ECB probes banks over exposure to Spanish drugmaker Grifols: sources	Jan. 17	RE
ECB sounds out lenders on exposure to Spanish drugmaker Grifols - sources	Jan. 17	RE
The Ibex-35 rebounds without leaving the range of the last month and a half.	Jan. 15	RE
Grifols Wins Assurance from Haier for Shanghai RAAS Stake Deal	Jan. 15	MT
Grifols says Haier Group still OK to buy stake in Shanghai RAAS	Jan. 14	RE
GRIFOLS: HAIER GROUP'S CHAIRWOMAN SAYS COMPANY CONTINUES TO WOR…	Jan. 14	RE
Grifols shares suffer worst week on record after short-seller report	Jan. 12	RE
Grifols foresees no problems in the sale of its stake in China despite Gotham City's report	Jan. 12	RE
Grifols to Finalize $1.8 Billion Shanghai RAAS Stake Sale as Planned in H1	Jan. 12	MT
Grifols sees no impact from Gotham report on China stake sale	Jan. 11	RE
GRIFOLS VICE CHAIR: WE SEE NO PROBLEM IN CLOSING SALE OF SHANGHA…	Jan. 11	RE
What does the Gotham City report say about Grifols?	Jan. 09	RE
What is Grifols and why have its shares slumped?	Jan. 09	RE
Grifols plunges after investment fund's doubts about its debt ratios	Jan. 09	RE
Gotham City accounting queries wipe $3 bln off Grifols value	Jan. 09	RE

Chart Shanghai RAAS Blood Products Co., Ltd.

Duration

Period

Chart Shanghai RAAS Blood Products Co., Ltd.

More charts

Company Profile

Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.07 CNY

Average target price

7 CNY

Spread / Average Target

-0.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.	-11.62%	6.48B
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.68%	29.36B
UCB	+57.79%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-13.47%	17.31B
INCYTE CORPORATION	-19.37%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+6.67%	8.31B

Biopharmaceuticals